Consolidated Medical Management Enters Agreement to Exchange Stock to Acquire MDEChem Inc.

Business Editors & Health/Medical Writers

HOUSTON--(BUSINESS WIRE)--Jan. 16, 2001

Consolidated Medical Management Inc. (OTCBB:CMMI) announced today that it has entered into a Agreement to Exchange Stock for the acquisition of MDEChem Inc. (Pink Sheets:MDKM). The acquisition is structured as an exchange of common shares and warrants by and between CMMI and the shareholders of MDEChem. Closing is anticipated to be on or before March 31, 2001, subject to completion of usual regulatory requirements and commercial conditions, including a MDEChem shareholders meeting.

MDEChem has rights to or owns intellectual property to several chemical compounds and products, derivative of its patented Phosfamid(TM) technology, including:

Pharmaceutical Products, including Maxheal, which exhibits great promise for acceleration of healing and anti-bacterial activity, currently in clinical and non-clinical trials of its product and is being used in South America. Maxheal's Principal Product has been tested and used for healing of infections in intractable wounds and in surgical procedures in humans and animals. Over 4,000 anecdotal and documented cases of its use upon Humans for various applications have confirmed its efficacy in acceleration of healing and anti-bacterial relief with very low levels of exhibited toxicity. Animal studies in pigs and cows in Costa Rica confirmed that it is highly effective in various veterinary and husbandry applications and uses. Maxheal is presently being used in Costa Rica and India, and requests for authority for sale and/or further testing are being applied for in countries in Central America and Africa. The potential for major skin care applications is enormous.

Fuel and Oil Additive Products that enhance engine performance, increase mileage and reduce potentially damaging emissions presently being tested for gasoline and diesel engines and motors. Blue Marble two-cycle engine oil is an inherently biodegradable product which is blended from highly refined, white mineral oil (baby oil), incorporating the advanced ash-less, anti-wear additive formula and. Traditional two-cycle engines, particularly used in small boats, use a gasoline/oil mixture whereby much of the unburned oil ends up in our lakes and streams, polluting them. Such pollution is spurring various forms of legislation banning the use of two-cycle engines in various States and mandating that manufacturers of such engines make modifications in compliance with new emission standards. Since MDEChem's Blue Marble oil is environmentally friendly, it has been very well-received by regulatory agencies and engine manufacturers worldwide and is presently pending various regulatory approvals.

Consolidated Medical Management, stated that the acquisition of MDEChem Inc. provides for future expansion into anticipated high-growth areas such as medicine, energy users and reduction of environmental pollution. We were extremely fortunate to be able to acquire MDEChem, particularly with its quality management and future prospects for world-wide medical applications. The acquisition is even more favorable considering MDEChem's energy efficient and environmentally favorable line of products. The range of potential medical applications for Maxheal appears to be extremely large. In addition, the Blue Marble line of products is undergoing testing in the United States, China and India. The MDEChem acquisition is the type of transaction Consolidated Medical Management needs to provide recurring revenues and profits. This is an asset which will increase shareholder value and long term profitability.

Frank DeFalco, president of MDEChem stated that he believed that the merger would accelerate the business operations of both companies, provide necessary management and marketing services for the medical and health care applications and promote rapid growth of its several products while reducing shared costs, thereby increasing shareholder value. We hope to serve medical, agricultural, municipal, industrial and individual consumers with the products we are developing.

Consolidated Medical Management Inc., with headquarters in Baton Rouge, La., is a provider of management services in the medical and health care industries. MDEChem has headquarters in Houston, and is a developer of pharmaceutical and chemical products.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The statements contained in this news release which are not historical facts are "forward-looking statements" that involve risks and uncertainties which could cause actual results to differ materially from those currently anticipated. For example, statements that describe Consolidated Medical Management's hopes, plans, objectives, goals, intentions, or expectations are forward-looking statements. The forward-looking statements made herein are only made as of the date of this news release. Numerous factors, many of which are beyond Consolidated Medical Management's control, will effect actual results. Consolidated Medical Management undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances. This news release should be read in conjunction with Consolidated Medical Management's annual report and Quarterly Reports and other filings with the U. S. Securities and Exchange Commission ("SEC"). MDEChem Inc., is a publicly held corporation that is not currently reporting with the SEC.